Literature DB >> 22015993

Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.

Yi-Bin Chen1, Julie Aldridge, Haesook T Kim, Karen K Ballen, Corey Cutler, Grace Kao, Deborah Liney, Greg Bourdeau, Edwin P Alyea, Philippe Armand, John Koreth, Jerome Ritz, Thomas R Spitzer, Robert J Soiffer, Joseph H Antin, Vincent T Ho.   

Abstract

There are little data comparing umbilical cord blood (UBC) and conventional stem cell sources for reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT). We performed a retrospective analysis of RIC HCST using double UCB (dUCB) grafts and RIC HSCT using unrelated donor (URD) grafts. The study included 64 dUCB transplantations and 221 URD transplantations performed at Dana-Farber Cancer Institute and Massachusetts General Hospital between 2004 and 2008. The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 14.1% for dUCB and 20.3% for URD (P = .32). The 2-year cumulative incidence of chronic GVHD was significantly lower in dUCB compared with URD (21.9% versus 53.9%; P < .0001). The 2-year cumulative incidence of nonrelapse mortality was significantly higher in dUCB (26.9% versus 10.4%; P = .0009). In our analysis, dUCB HSCT and URD HSCT had comparable 3-year overall survival (46% in dUCB and 50% in URD; P = .49) and progression-free survival (30% in dUCB and 40% in URD; P = .47). dUCBT was associated with greater nonrelapse mortality despite less chronic GVHD. Our findings suggest that the use of 2 partially matched UCB units appears to be a suitable alternative for patients undergoing RIC HSCT without an HLA-matched donor.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015993     DOI: 10.1016/j.bbmt.2011.10.016

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  31 in total

1.  A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies.

Authors:  U Sobol; A Go; S Kliethermes; S Bufalino; T Rodriguez; S Smith; M Parthasarathy; P Stiff
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

2.  Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies.

Authors:  Gunjan L Shah; Leyla Shune; Duncan Purtill; Sean Devlin; Emily Lauer; Marissa Lubin; Valkal Bhatt; Courtney McElrath; Nancy A Kernan; Andromachi Scaradavou; Sergio Giralt; Miguel A Perales; Doris M Ponce; James W Young; Monica Shah; Genovefa Papanicolaou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-10       Impact factor: 5.742

Review 3.  Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors?

Authors:  Hongtao Liu; Koen van Besien
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

4.  No Synergistic Effect of Cotransplantation of MSC and Ex Vivo TPO-Expanded CD34(+) Cord Blood Cells on Platelet Recovery and Bone Marrow Engraftment in NOD SCID Mice.

Authors:  Mark van der Garde; Anneke Brand; Manon C Slot; Alice de Graaf-Dijkstra; Jaap Jan Zwaginga; Yvette van Hensbergen
Journal:  Stem Cells Dev       Date:  2015-03-13       Impact factor: 3.272

5.  Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.

Authors:  Karen K Ballen; Steven Joffe; Ruta Brazauskas; Zhiwei Wang; Mahmoud D Aljurf; Görgün Akpek; Christopher Dandoy; Haydar A Frangoul; César O Freytes; Nandita Khera; Hillard M Lazarus; Charles F LeMaistre; Paulette Mehta; Susan K Parsons; David Szwajcer; Celalettin Ustun; William A Wood; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-23       Impact factor: 5.742

Review 6.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

Review 7.  Umbilical cord blood donation: public or private?

Authors:  K K Ballen; F Verter; J Kurtzberg
Journal:  Bone Marrow Transplant       Date:  2015-06-01       Impact factor: 5.483

8.  Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.

Authors:  D M Ponce; A Gonzales; M Lubin; H Castro-Malaspina; S Giralt; J D Goldberg; A M Hanash; A Jakubowski; R Jenq; E B Papadopoulos; M A Perales; M R M van den Brink; J W Young; F Boulad; R J O'Reilly; S Prockop; T N Small; A Scaradavou; N A Kernan; C E Stevens; J N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-14       Impact factor: 5.742

9.  Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice.

Authors:  Duncan Purtill; Katherine Smith; Sean Devlin; Richard Meagher; Joann Tonon; Marissa Lubin; Doris M Ponce; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Cladd E Stevens; Juliet N Barker
Journal:  Blood       Date:  2014-09-02       Impact factor: 22.113

10.  Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.

Authors:  Karen Ballen; Kwang Woo Ahn; Min Chen; Hisham Abdel-Azim; Ibrahim Ahmed; Mahmoud Aljurf; Joseph Antin; Ami S Bhatt; Michael Boeckh; George Chen; Christopher Dandoy; Biju George; Mary J Laughlin; Hillard M Lazarus; Margaret L MacMillan; David A Margolis; David I Marks; Maxim Norkin; Joseph Rosenthal; Ayman Saad; Bipin Savani; Harry C Schouten; Jan Storek; Paul Szabolcs; Celalettin Ustun; Michael R Verneris; Edmund K Waller; Daniel J Weisdorf; Kirsten M Williams; John R Wingard; Baldeep Wirk; Tom Wolfs; Jo-Anne H Young; Jeffrey Auletta; Krishna V Komanduri; Caroline Lindemans; Marcie L Riches
Journal:  Biol Blood Marrow Transplant       Date:  2016-06-22       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.